A citation-based method for searching scientific literature

Alex Mas Monteys, Shauna A Ebanks, Megan S Keiser, Beverly L Davidson. Mol Ther 2017
Times Cited: 155



Ian M Slaymaker, Linyi Gao, Bernd Zetsche, David A Scott, Winston X Yan, Feng Zhang. Science 2016
Times Cited: 1294




List of shared articles



Times cited

CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders.
Lihong Guan, Yawei Han, Ciqing Yang, Suxiang Lu, Jiang Du, Han Li, Juntang Lin. Mol Neurobiol 2022
2

CRISPR/Cas therapeutic strategies for autosomal dominant disorders.
Salvatore Marco Caruso, Peter Mj Quinn, Bruna Lopes da Costa, Stephen H Tsang. J Clin Invest 2022
0

Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect.
Yu-Fan Chuang, Andrew J Phipps, Fan-Li Lin, Valerie Hecht, Alex W Hewitt, Peng-Yuan Wang, Guei-Sheung Liu. Cell Mol Life Sci 2021
12

Precise CAG repeat contraction in a Huntington's Disease mouse model is enabled by gene editing with SpCas9-NG.
Seiya Oura, Taichi Noda, Naoko Morimura, Seiji Hitoshi, Hiroshi Nishimasu, Yoshitaka Nagai, Osamu Nureki, Masahito Ikawa. Commun Biol 2021
1

The Off-Targets of Clustered Regularly Interspaced Short Palindromic Repeats Gene Editing.
Manuel M Vicente, Miguel Chaves-Ferreira, João M P Jorge, João T Proença, Vasco M Barreto. Front Cell Dev Biol 2021
3

A glance at genome editing with CRISPR-Cas9 technology.
Antara Barman, Bornali Deb, Supriyo Chakraborty. Curr Genet 2020
21

CRISPR Diagnosis and Therapeutics with Single Base Pair Precision.
Seung Hwan Lee, Young-Ho Park, Yeung Bae Jin, Sun-Uk Kim, Junho K Hur. Trends Mol Med 2020
14

Allele-specific genome targeting in the development of precision medicine.
Junjiao Wu, Beisha Tang, Yu Tang. Theranostics 2020
11

Genome and base editing for genetic hearing loss.
Philipp Niggemann, Bence György, Zheng-Yi Chen. Hear Res 2020
10

Mutation-Independent Allele-Specific Editing by CRISPR-Cas9, a Novel Approach to Treat Autosomal Dominant Disease.
Kathleen A Christie, Louise J Robertson, Caroline Conway, Kevin Blighe, Larry A DeDionisio, Connie Chao-Shern, Amanda M Kowalczyk, John Marshall, Doug Turnbull, M Andrew Nesbit,[...]. Mol Ther 2020
4

CRISPR-Cas9 system: A genome-editing tool with endless possibilities.
Swati Tyagi, Robin Kumar, Aparup Das, So Youn Won, Pratyoosh Shukla. J Biotechnol 2020
13

Mutation-Specific Guide RNA for Compound Heterozygous Porphyria On-target Scarless Correction by CRISPR/Cas9 in Stem Cells.
Florence Prat, Jérôme Toutain, Julian Boutin, Samuel Amintas, Grégoire Cullot, Magalie Lalanne, Isabelle Lamrissi-Garcia, Isabelle Moranvillier, Emmanuel Richard, Jean-Marc Blouin,[...]. Stem Cell Reports 2020
4

CRISPR to the Rescue: Advances in Gene Editing for the FMR1 Gene.
Carolyn M Yrigollen, Beverly L Davidson. Brain Sci 2019
9

Allele-Specific CRISPR/Cas9 Correction of a Heterozygous DNM2 Mutation Rescues Centronuclear Myopathy Cell Phenotypes.
Aymen Rabai, Léa Reisser, Bernardo Reina-San-Martin, Kamel Mamchaoui, Belinda S Cowling, Anne-Sophie Nicot, Jocelyn Laporte. Mol Ther Nucleic Acids 2019
11

Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases.
Panayiota Papasavva, Marina Kleanthous, Carsten W Lederer. Mol Diagn Ther 2019
18

Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.
Sudhanshu P Raikwar, Nidhi S Kikkeri, Ragha Sakuru, Daniyal Saeed, Haris Zahoor, Keerthivaas Premkumar, Shireen Mentor, Ramasamy Thangavel, Iuliia Dubova, Mohammad Ejaz Ahmed,[...]. J Neuroimmune Pharmacol 2019
10